<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560036</url>
  </required_header>
  <id_info>
    <org_study_id>19-5849</org_study_id>
    <nct_id>NCT04560036</nct_id>
  </id_info>
  <brief_title>FAZA PETMRI Gastro-Oesophageal Study</brief_title>
  <official_title>Hypoxia Measurement With FAZA PET/MRI in Patients With Metastasized Gastro-Oesophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, pilot study of PET/MRI scan with radiotracer 18F-Fluoroazomycin&#xD;
      Arabinoside (FAZA) before and after standard of care platinum-based chemotherapy for patients&#xD;
      with metastasized Gastro-Oesophageal Cancer.&#xD;
&#xD;
      Gastroesophageal cancer (GEC) accounted for 2,3000 deaths in Canada in 2017 and majority of&#xD;
      the patients present or develop metastatic disease following diagnosis. These patients are&#xD;
      treated with platinum-based chemotherapy. There is currently no biomarker that can be used to&#xD;
      predict the therapy responses. Additionally, patients that do not respond to the chemotherapy&#xD;
      often deteriorate rapidly and are unable to receive second line therapy. Intratumoral hypoxia&#xD;
      (low oxygen concentration) is a signature feature of aggressive and resistant tumour&#xD;
      phenotype. Accurately predicting hypoxia in solid tumours offers an innovative and rational&#xD;
      pradigm for predicting therapy responses. PET/MRI is an imaging technique combining the&#xD;
      Positron Emission Tomography (PET) scan with Magnetic Resonance Imaging (MRI) scan. A&#xD;
      radiotracer called 18F-Fluoroazomycin Arabinoside (FAZA) is used as a type of &quot;dye&quot; in the&#xD;
      PET/MRI scan.&#xD;
&#xD;
      The primary goal of the study is to validate FAZA PET/MRI as a biomarker of hyupoxia in&#xD;
      setting of gastro-oesophageal carcinoma. Patients with GEC will undergo FAZA PET/MRI scan&#xD;
      before and after the standard of care chemotherapy. This would be correlated with clinical&#xD;
      outcome in patients with metastatic GEC that have different responses to chemotherapy.&#xD;
      Ultimately, we hope that the use FAZA PET/MRI in the study can help select the most effective&#xD;
      treatment method for advanced GEC to extend life and improve quality of life while minimizing&#xD;
      toxicity and healthcare costs.&#xD;
&#xD;
      The study subjects' clinical management will not be changed based on the PET-MR scan within&#xD;
      the trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>FAZA PET/MRI scan</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of FAZA PET/MRI as a biomarker of hypoxia</measure>
    <time_frame>two weeks before chemotherapy</time_frame>
    <description>The FAZA uptake during the first PET/MRI scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validation of FAZA PET/MRI as a biomarker of hypoxia</measure>
    <time_frame>3 months after the chemotherapy</time_frame>
    <description>The FAZA uptake during the 2nd PET/MRI scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate tumour marker ctDNA in blood samples</measure>
    <time_frame>two weeks before chemotherapy</time_frame>
    <description>Evaluate tumour marker ctDNA in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate tumour marker ctDNA in blood samples</measure>
    <time_frame>6 weeks after initiation of chemotherapy</time_frame>
    <description>Evaluate tumour marker ctDNA in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate tumour marker ctDNA in blood samples</measure>
    <time_frame>3 months after chemotheray</time_frame>
    <description>Evaluate tumour marker ctDNA in blood samples</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastasized Gastro-Oesophageal Cancer</condition>
  <arm_group>
    <arm_group_label>FAZA PET/MRI scan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FAZA PET/MRI scan before and after the standard of care chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FAZA PET/MRI scan</intervention_name>
    <description>FAZA PET/MRI scan before and after the standard of care chemotherapy</description>
    <arm_group_label>FAZA PET/MRI scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
          -  Patients with de novo or secondary metastasized gastro-oesophagesal cancer&#xD;
             (adenocarcinoma)&#xD;
&#xD;
          -  Glomerular Filtration rate&gt; 45 ml/min&#xD;
&#xD;
          -  No allergy to contrast agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication for MR as per current institutional guidelines&#xD;
&#xD;
          -  Inability to lie supine for at least 30 minutes&#xD;
&#xD;
          -  Any patient who is pregnant or breastfeeding&#xD;
&#xD;
          -  Any patient unable or unwilling to provide informed consent&#xD;
&#xD;
          -  Patients who are allergic to ethanol as the FAZA preparation contains ethanol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Veit-Haibach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iris Zhong</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>4816</phone_ext>
    <email>iris.zhong@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univeristy Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Zhong</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>4816</phone_ext>
      <email>iris.zhong@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Patrick Veit-Haiback, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>April 11, 2021</last_update_submitted>
  <last_update_submitted_qc>April 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

